Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680036 | 0.85 | CNR1 (0.33) | EPHX2 | |
| SCHEMBL2225425 | 0.78 | — | — | |
| SCHEMBL27716512 | 0.78 | PKM (0.36) | — | |
| SCHEMBL15794940 | 0.75 | — | — | |
| SCHEMBL28626663 | 0.75 | EPHX1 (0.34) | EPHX2EPHX1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL15655416 | 0.74 | SCN9A (0.30) | — | |
| SCHEMBL27746258 | 0.73 | EPHX1 (0.41) | EPHX2EPHX1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL1787822 | 0.73 | EPHX1 (0.41) | EPHX2EPHX1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL908356 | 0.72 | ALDH1A1 (0.46) | EPHX2EPHX1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3841283 | 0.71 | CTSK (0.54) | TP53EPHX2EPHX1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152714-B1 | SPIROINDOLINONE DERIVATIVES AS MDM2-p53 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-7834179-B2 | 6',7',8',9'-tetrahydro spiro[3H-indole-3,7'-(2H-pyrido[2,1-c][1,2,4]triazine)]-2,3'(1H)-dione compounds; small molecule inhibitors of the MDM2-p53 interaction | HOFFMANN-LA ROCHE INC. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1996590-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20090318500-A1 | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-7615634-B2 | 4-aminopyrimidine-5-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1996590-A1 | SPIROINDOLINONE DERIVATIVES | F. Hoffmann-la Roche AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080293723-A1 | SPIROINDOLINONE DERIVATIVES | LIU JIN-JUN | 2008-11-27 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2007104664-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213341-A1 | Spiroindolinone derivatives | CHEN LI | 2007-09-13 | — | — | US | disclosed |
| US-7157455-B2 | 4-Aminopyrimidine-5-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060229330-A1 | 4-aminopyrimidine-5-one derivatives | BARTKOVITZ DAVID J | 2006-10-12 | — | — | US | disclosed |
| US-20040162303-A1 | 4-aminopyrimidine-5-one derivatives | BARTKOVITZ DAVID JOSEPH (US) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | RB1, PKD1, KRAS | TP53 30/4885EPHX2 3338/4885EPHX1 2408/4885 |
| US-20040162303-A1 | 4-aminopyrimidine-5-one derivatives | CDK4, CDKL4, CDK6 | TP53 89/4885EPHX2 3643/4885EPHX1 3432/4885 |
| US-20070213341-A1 | Spiroindolinone derivatives | MKI67, PKD1, RCC2 | TP53 25/4885EPHX2 3018/4885EPHX1 2658/4885 |
| US-20090318500-A1 | 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA5A, PDK4 | TP53 7/4885EPHX2 2909/4885EPHX1 3223/4885 |
| US-20060229330-A1 | 4-aminopyrimidine-5-one derivatives | CDK4, CDKL4, CDK2 | TP53 72/4885EPHX2 4385/4885EPHX1 4161/4885 |
| US-20080293723-A1 | SPIROINDOLINONE DERIVATIVES | RB1, SIRT3, AR | TP53 35/4885EPHX2 4352/4885EPHX1 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.